52 related articles for article (PubMed ID: 9657622)
41. Cardiac and vascular remodelling: effect of antihypertensive agents.
Mallion JM; Baguet JP; Siche JP; Tremel F; De Gaudemaris R
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S35-41; discussion S49-50. PubMed ID: 10076919
[TBL] [Abstract][Full Text] [Related]
42. Structural cardiovascular alterations and blood pressure variability in human hypertension.
Mancia G; Giannattasio C; Turrini D; Grassi G; Omboni S
J Hypertens Suppl; 1995 Aug; 13(2):S7-14. PubMed ID: 8576791
[TBL] [Abstract][Full Text] [Related]
43. Cardiac effects of isradipine in patients with hypertension.
Lund-Johansen P
Am J Hypertens; 1993 Jul; 6(7 Pt 2):294S-299S. PubMed ID: 8398014
[TBL] [Abstract][Full Text] [Related]
44. Left ventricular hypertrophy and arterial blood pressure in experimental models of hypertension.
Dominiczak AF; Devlin AM; Brosnan MJ; Anderson NH; Graham D; Clark JS; McPhaden A; Hamilton CA; Reid JL
Adv Exp Med Biol; 1997; 432():23-33. PubMed ID: 9433508
[TBL] [Abstract][Full Text] [Related]
45. Regression of LVH or improved prognosis (or both): what is the question?
Lip GY; Lydakis C; Zarifis J; Messerli FH
J Hum Hypertens; 1998 Jul; 12(7):423-5. PubMed ID: 9702926
[No Abstract] [Full Text] [Related]
46. The importance of sustained blood pressure control.
Meredith PA
J Cardiovasc Pharmacol; 2000; 35 Suppl 3():S7-11. PubMed ID: 10854045
[TBL] [Abstract][Full Text] [Related]
47. Missing Link between Molecular Aspects of Ventricular Arrhythmias and QRS Complex Morphology in Left Ventricular Hypertrophy.
Bacharova L
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861705
[TBL] [Abstract][Full Text] [Related]
48. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity.
Manolis AJ; Beldekos D; Handanis S; Haralabidis G; Hatzissavas J; Foussas S; Cokkinos DV; Bresnahan M; Gavras I; Gavras H
Am J Hypertens; 1998 Jun; 11(6 Pt 1):640-8. PubMed ID: 9657622
[TBL] [Abstract][Full Text] [Related]
49. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
50. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
Dahlöf B
Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
[TBL] [Abstract][Full Text] [Related]
51. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
Dahlöf B
J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
[TBL] [Abstract][Full Text] [Related]
52. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
